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Abstract 
As the global health burden of chronic disease increases, end-stage organ 
failure has become a costly and intractable problem. De novo organ creation 
is one of the long-term goals of the medical community. One of the promising 
avenues is that of tissue engineering: the use of biomaterials to create cells, 
structures, or even whole organs. Tissue engineering has emerged from its 
nascent stage, with several proof-of-principle trials performed across various 
tissue types. As tissue engineering moves from the realm of case trials to 
broader clinical study, three major questions have emerged: 1) Can the 
production of biological scaffolds be scaled up accordingly to meet current 
and future demands without generating an unfavourable immune response? 
2) Are biological scaffolds plus or minus the inclusion of cells replaced by scar 
tissue or native functional tissue? 3) Can tissue-engineered organs be grown 
in children and adolescents given the different immune profile of children? In 
this review, we highlight current research in the immunological response to 
tissue engineered biomaterials, cells, and whole organs and attempt to 
provide the answers to these questions. 
  
Introduction 
End-stage organ failure is one of the most devastating and costly problems 
facing modern medicine [1]. An ever increasing number of individuals join the 
organ donor register, but there is still a dearth of supply [2]. In 1989, there 
were 17,917 patients in the United States registered on the combined active 
and suspended solid organ transplant waiting lists. By 2015, this number had 
risen to 79,062 active patients with a further 44,334 on the temporary 
suspension list to total 123,396 individuals [3]. Approximately 21 patients die 
each day waiting for a transplant that will never happen due to the national 
shortage of available organs [4]. While solid organ transplantation has been in 
place for over half a century, the fortunate recipients are relegated to lifelong 
immune suppression with the associated increased morbidity and mortality. 
The gold-standard solution of “off-the-shelf” organs that are non-immunogenic 
and have the viability of the host has yet to be achieved. Tissue engineering 
has long been a much-heralded tool that could, in theory, provide organs for 
those unable to receive conventional allotransplants. 
 
Tissue engineering was pioneered in 1933 when Bisceglie [5] first 
demonstrated that mouse tumour cells, when encased in a polymer in the 
abdominal cavity of the pig, did not mount an immune response. When 
Macchiarini and colleagues performed proof-of-principle studies in pigs, the 
prospect of human organ tissue engineering trials resurfaced [6]. Pioneered in 
the airway with tracheal transplantation, studies have progressed to 
investigate tissue-engineered transplants in humans involving the nose, 
genital tract small bowel, lung, urethra and liver, among others [7-13]. These 
tissue engineered constructs may comprise scaffolds only, cells only, or both 
combinations of scaffolds and cells. Scaffolds may be allogenic, xenogenic, or 
synthetic in origin and can be seeded with autologous cells. The nascent days 
of this technology have been challenging but also rewarding. 
 
All of the patients that have undergone these procedures have received 
transplants on compassionate grounds as a palliative measure in an attempt 
to extend or significantly improve quality of life (Table 1). In light of the 
published case trials on the background of the publication of a five-year 
follow-up to the first tissue engineered transplant, we have reached a turning 
point for tissue engineering organs [14]. Grafts are generally safe and well 
tolerated, but their utility has yet to be demonstrated on a larger scale. The 
first clinical trial of this technique is due to begin in 2015 (RegenVox study). 
 
Nevertheless, the early studies reveal host immune response to the graft has 
profound effects on the viability and durability of the graft. Grafts may be 
immunogenic (capable of triggering an immune response), antigenic (capable 
of binding and interacting with the host but not necessarily causing an 
immune response), or both. How immunogenic a graft is depends on a variety 
of factors including graft complexity, insolubility, and protein content. 
Furthermore, the “dose” of the graft, how many grafts are required, the route 
in which the graft is delivered, the location of the graft, and any knock on 
treatment that is required all affect the extent and type of immune response 
that occurs. Finally, the immune response is not all deleterious; immune 
modulation and graft remodelling may be valuable tools for improving graft 
outcomes. 
 
The immune response to the graft is mediated by the innate and adaptive 
immune systems. The innate immune system is the omnipresent first line of 
immune response. Phagocytic white blood cells, dendritic cells, Natural Killer 
(NK) cells, and plasma proteins identify microbes immediately at the site of 
infection. The adaptive immune response responds to pathogens that have 
overcome the innate immune system and, in doing so, develops “memory” of 
the microbe. The adaptive system has two arms: the cell-mediated and 
humoral immune responses. The cell-mediated response involves peptide-
induced T cell activation, giving rise to helper T cells and cytotoxic T cells. 
Helper T cells secrete products that aid macrophages and B cells whereas 
cytotoxic T cells are actively involved in the destruction of pathogens. The 
humoral response, in contrast, relies on circulating antigens to trigger 
maturation of B cells into antibody secreting plasma cells. Antibody secreting 
plasma cells are specific for a certain microbe, “marking” their target for 
destruction by phagocytes. The inappropriate identification of a graft as 
“foreign” leads to graft rejection, graft versus host disease, and graft failure. 
Current research is focused on both identifying the fate of grafts as well as 
developing novel strategies of harnessing the host immune response to 
tolerate the graft. 
 
Ref Author Year Patients Transplant Type Mortality Graft-
related? 
Trachea 
[15] Macchiarini 2008 1 Adult Allogenic scaffold + 
autologous cells 
0 N/A 
[16] Omori 2008 4 Adults Synthetic scaffold + 
collagen coating 
0 N/A 
[17] Jungebluth 2011 1 Adult Synthetic scaffold + 
autologous cells 
NR NR 
[18] Delaere 2012 5 Adults Allogenic scaffold + 
autologous cells 
NR NR 
[19] Elliott 2012 1 Child Allogenic scaffold + 
autologous cells 
0 N/A 
[20] Berg 2013 1 Adult Allogenic scaffold + 
autologous cells 
1 No 
Oesophagus 
[21] Ohki 2013 9 Adults Autologous epithelial 
cells 
0 N/A 
Blood vessels/ vascular grafts 
[22] Mertsching 2009 1 Adult Xenogenic scaffold + 
autologous cells 
0 N/A 
[23] Hibino 2010 25 Children Autologous bone 
marrow + autologous 
cells 
0 N/A 
[12] Olausson 2012 1 Child Allogenic scaffold + 
autologous cells 
0 N/A 
[24] Olausson 2014 2 Children Allogenic scaffold + 
autologous cells 
0 N/A 
Bladder 
[9] Atala 2006 7 Adults Synthetic scaffold + 
autologous cells 
0 N/A 
[11] Raya-Rivera 2011 5 Children Synthetic scaffold + 
autologous cells 
0 N/A 
Vagina 
[8] Raya-Rivera 2014 4 Children Allogenic scaffold + 
autologous cells 
0 N/A 
Muscle 
[25] Mase 2010 1 Adult Synthetic scaffold 0 N/A 
[26] Sicari 2014 5 Adults Xenogenic scaffold + 
autologous cells 
0 N/A 
Cartilage 
[27] Brittberg 1994 23 Adults Autologous 
chondrocytes 
0 N/A 
[28] Almqvist 2009 21 Adults Synthetic scaffold + 
allogenic chondrocytes 
0 N/A 
[29] Lim 2009 Unknown; 
ongoing 
Mesenchymal stem 
cells 
NR NR 
Nose 
[13] Fulco 2014 5 Adults Autologous 
condrocytes 
0 N/A 
Heart valves 
[30] Cebotari 2006 2 Children PV allografts + 
autologous cells 
0 N/A 
 Tissue engineering therefore presents important questions regarding the role 
of the host immune response. 1) Can the production of biological scaffolds be 
scaled up accordingly to meet current and future demands without generating 
an unfavourable host immune response? (discussed here in section 1) 2) Are 
biological scaffolds plus or minus the inclusion of cells replaced by scar tissue 
or native quality tissue? (discussed here in sections 2 and 3) 3) Can tissue-
engineered organs be grown in children and adolescents in spite of the 
specific immune profile of children? (discussed here in section 4) [36]  
 
The purpose of this review is to discuss the role of the host immune system in 
confounding or promoting the advancement of organ tissue engineering and 
the areas of research that are promising. 
 
1 The immune response to synthetic, biological, and xenogenic 
biomaterials  
[31] Dohmen 2011 11 Adults PV allograft + 
autologous cells 
0 N/A 
[32] Kneib 2012 12 Adults 6 AVs + 5 PV allografts 
+/- autologous cells 
0 N/A 
Bone 
[33] Vacanti 2001 1 Adult Synthetic scaffold + 
autologous cells 
0 N/A 
Skin 
[34] O’Connor 1981 2 Adults Autologous skin 0 N/A 
Cornea 
[35] Pellegrini 1997 2 Adults Autologous cells 0 N/A 
Table 1: Key cases of tissue engineering transplants in adults and 
pediatrics. N/A: Not applicable. NR: Not reported. 
Whole organ tissue engineering requires the use of scaffolds on which to 
seed cells for soft tissue regeneration. Scaffolds can be constructed de novo 
using synthetic or biological materials or derived from allogenic and xenogenic 
tissues. The choice of materials is increasingly complex; Figure 1 
demonstrates the current possibilities for skeletal muscle reconstruction alone. 
Although the choice of biomaterials has been reviewed elsewhere [37], here 
we provide an overview of the immunological profile of the biomaterials used 
in scaffolds (Table 2). 
 
Figure 1: Schematic overview of scaffold materials used for skeletal muscle 
reconstruction in tissue engineering (Reproduced with permission from [38])  
1.1 Synthetic biomaterials  
Synthetic biomaterials are widely available and already have many uses 
within medicine. Examples include hydrogel, plastic, polystyrene, and gold 
[39]. The advantages of synthetic materials are clear: they are largely inert, 
mass producible, and can be tailored to meet the specific requirements of the 
organ in question. Their hydrolytic properties mean that even their 
degradation profile can be controlled and manipulated [40]. Unfortunately, 
synthetic biomaterials are among the most immunogenic biomaterials, 
strongly activating the innate immune system. Recent research has 
demonstrated that, through their effects on toll like receptors, synthetics 
trigger pathogen associated molecular proteins and local inflammasomes, 
causing widespread damage at the graft site [41]. One potential tool to 
circumvent the immune profile of synthetics is to use peptides or other 
biologicals to coat the surface of synthetic biomaterials [42]. An even more 
sophisticated approach would be to coat a synthetic material with a 
modulatory extracellular matrix in order to modulate the host response [41]. 
 1.2 Biological de novo biomaterials  
Biological biomaterials that can be constructed de novo into scaffolds include 
collagen [42], fibrinogen, hyaluronic acid, GAGs, hydroxyapatite, chitosan, silk 
[43] and starch [44]. De novo biological materials are promising because they 
are readily available, cost-effective, and able to be produced in large numbers. 
Concerns include their intrinsic biophysical properties (tensile strength, 
contractility, etc), degradation profiles, sterilisation cost, and pathogenic 
potential. Studies of starch-based scaffolds implanted subcutaneously and 
intramuscularly suggest good integration of the materials in the host 
independent of the tissue location [44]. Silk-based biomaterials provoke an 
untransformed CD14+ human monocyte response characterized by IL-1β (an 
inflammatory cytokine) and IL-6 (an acute phase reactant) but not IL-10 (anti-
inflammatory) gene expression and protein production [43]. The macrophage 
response to silk is mostly mediated by the sericin protein [45]. Large silk 
biomaterials fail to induce peripheral T cell activation, an interesting finding 
that merits further study. Current hypotheses include a role for expression 
markers that down-regulate T cell responsiveness [43]. Silk could therefore 
find several implementations: as a surgical device to replace conventional 
mesh, as a cloak for other biomaterials, or as a research device for further 
elucidating T cell downregulation.  
 
 1.3 Xenogenic biomaterials  
An ideal biomaterial would have adequate biomechanical properties, be 
readily available, promote a favourable immune response, and present a low 
risk for infectious disease transmission [22]. The use of xenogenic material is 
therefore particularly suitable. However, the immunogenicity of xenogenic 
biomaterials is still the primary drawback to their use. Heart valves, the 
ubiquitous usage of a xenogenic biomaterial, are still subject to immune 
mediated degradation in an area that has a minimal immune response [46].  
The Gal epitope has been the most studied in this context. For example, pig 
to primate liver transplantation with livers transgenic for human CD55 (which 
mediates complement activation) or α-1,3-galactosyltransferase knockout was 
associated with extended survival [47, 48]. Although modifying the Gal 
epitope may mitigate acute rejection, there is still a delayed form of antibody-
mediated rejection. There are most likely to be non-Gal based xenoantigens, 
although these have yet to be fully identified [49, 50]. Ideally, a xenogenic 
scaffold could be decellularized and modified to the point where acute and 
chronic rejection were minimized. 
 
One potential route to the use of xenogenic biomaterial is through 
immunoisolation: when the foreign material is immunologically isolated from 
the surrounding tissues [51-53]. There are two mechanisms by which 
immunoisolation can occur: encapsulation and immunocloaking. Lim and Sun 
pioneered this technique in 1980 when they found that encapsulated islets 
correct diabetes in rats [54]. Modern encapsulation techniques use 
extravascular (membrane/ hollow fibres) or intravascular (like dialysis) 
techniques in order to contain islets. These capsules permit oxygen, nutrient, 
and molecular exchange to a degree but prevent large immune molecules 
from passing [55]. Immunocloaking is an alternative technique in which a 
natural nanofilm is injected prior to transplantation in order to camouflage 
antigens [53]. For example, Brasile et al used a nano-barrier membrane to 
cover canine kidneys in a renal transplant model. No immune suppression 
was required, and the mean rejection time was 30 days versus 6 days 
untreated [56]. Although both of these mechanisms are promising, they still 
require some degree of immune suppression. Using silk as a cloak would be 
an interesting avenue for further exploration. However, it is still not clear what 
catastrophic results would occur if and when degradation of the protective 
coating began. 
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2 The immune response to allogenic biomaterials 
 2.1 Decellularisation and immunogenicity  
Allogenic biomaterials are those derived from another host that have been 
modified in order to function as a graft. Allogenic materials are advantageous 
because they maintain tissue composition and architecture and are very 
similar to the native tissues they aim to replace. Hypothetically, allogenic 
materials can be harnessed to both remodel and regenerate a host tissue 
while circumventing the immune response [57, 58]. Considerable research 
has focused on creating non-immunogenic allogenic materials. One of the first 
steps in “treating” an allogenic biomaterial is to decellularize the graft. The 
ultimate aim of decellularisation techniques is the removal of antigens that 
elicit an adverse immune response while preserving scaffold (i.e., ECM) 
integrity. This integrity is typically measured through collagen, elastin, s-
glycosaminoglycan, and growth factor content, as well as structural and 
ultrastructural integrity. Cryofixation with glutaraldehyde and preservation and 
fixation [30] been attempted but generated non-viable grafts.  
 
One early method, pioneered by Yates et al, removes 98.2% of nucleated 
cells and 98.7% of soluble protein in bone via wash and centrifugation steps 
[59]. Decellularisation methods have developed since then with a wide variety 
of results both in terms of functionality and structural content [60-62]. It is 
important to note that the two do not entirely correlate [63].  However, in a 
recent study, rabbit cricoarytenoid dorsalis muscles were harvested and 
analysed using different methods: histochemical, immunohistochemical, and 
molecular. Latrunculin B, potassium iodide, potassium chloride, and 
deoxyribonuclease all led to total DNA clearance, decreased MHC II 
expression, and preservation of structural integrity [57]. Most protocols are 
prohibitive due to the time (28 days) required to produce the scaffold and the 
resultant financial costs. Most recently, Lange et al have described an 
enzyme/detergent protocol which, when combined with vacuum technology, 
can significantly reduce the time required to create clinically suitable airway 
scaffolds [64]. However, this method is not necessarily applicable to all tissue 
sources and tissue types of biological scaffolds as these techniques have 
been primarily focused on airway structures. Developing an appropriate test 
for the immunogenicity or antigenicity of a scaffold will be important as the 
levels of MHC I and II and the structural integrity alone are not predictive. 
 
Decellularised scaffolds can also modulate the immune response of their 
hosts with decreased T cell proliferation and a shift towards the M2 
macrophage phenotype [58, 65]. For allogenic and xenogenic materials, the 
tissue remnants after decellularization may still provoke an innate immune 
response. For example, Damage Associated Molecular Proteins (DAMPs) 
may still be present after decellularization. These DAMPs are not only found 
in the native tissue but they are also actively secreted during cell necrosis and 
by macrophages that respond to the acute tissue injury. DAMPs upregulate 
HMGB1, which mediates the proinflammatory response through increased 
chemokine and TLR4 mRNA expression [66]. Counterintuitively, minimizing 
this initial macrophage response by inhibiting a well-characterized DAMP, 
HMGB1, led to an increase in the proinflammatory response, cell death, and 
chemokine expression [66]. There is therefore a potential for DAMPs to be 
manipulated as bioinductive molecules within an ECM scaffold. 
 
Decellularization also does not, however, fully remove MHC I and II [67].  
Interestingly, Haykal et al noted that decellularization delays leukocyte 
involvement but leads to cartilage degradation [67]. Macrophages are very 
plastic and can switch from M1 to M2 in response to the environment [68, 69]. 
In theory, the injury caused by inserting a decellularized scaffold can 
modulate the macrophage response to an immunotolerant, injury response 
M2 macrophage type [70, 71] (See Section 4.1). Macrophage repolarization 
could lead to site-appropriate remodelling [72, 73], and is therefore a valuable 
direction of future study. 
 
The immune response to decellularised scaffolds has raised questions and 
offered solutions for harnessing the immune response to scaffolds (See 
Section 4.1). Recellularising grafts with autologous cells alters the immune 
response to these grafts (See Section 2.2).  
 2.2 Recellularisation and immunogenicity  
Once scaffolds have been decellularized, recellularization with appropriate 
cells is the ultimate goal. Which cells to use and when to use them are 
questions that have been addressed elsewhere [74]. Recently, one group has 
grown three individual scaffolds: the epithelial (physical barrier), fibroblast 
(ECM production), and dendritic cell (immune sensing) layers. The epithelial 
layer in particular was grown at the air-liquid interface for four weeks leading 
to a functional barrier and transepithelial electrical resistance mediated by 
tight junctions [75]. As regards the immune response towards these new cells, 
cellularization provides an important opportunity to modulate the immune 
response. 
 
Stem cells can be loaded with the required genes prior to incubation. For 
example, Holladay et al found that, when stem cells were transfected with IL-
10 before being loaded onto a collagen scaffold, there was a significant 
improvement in the survival of the cells [76]. Such techniques should be 
approached with caution. For example, although some factors, such as FGF, 
activate the key regenerative processes of inflammation, wound response, 
and chemotaxis, they also provoke a strong immune response [77]. 
Incorporating the use of external factors in promoting cellularization and graft 
survival is still in its nascent stages. In one of the human cases, a 12-year old 
boy with congenital tracheal stenosis was transplanted with a scaffold seeded 
with bone marrow mesenchymal stem cells and granulocyte-colony 
stimulating factor with recombinant erythropoietin and transforming growth 
factor beta applied. A subsequent strong neutrophil response at 8 weeks 
generated neutrophil extracellular traps, which considerably affected mucosal 
clearance [19]. Therefore, current efforts focus on the use of autologous cells 
rather than stem cells. 
 
Using autologous cells prior to implantation initially requires a bioreactor. 
Ideally, the bioreactor presents a similar environment to the host optimal for 
cell growth and integration [41]. For example, lymph nodes have been 
assessed in mice as scaffolds. The lymph nodes were processed using 
sodium dodecyl sulfate detergent, and the matrices were repopulated with 
splenocytes, implanted in submuscular pockets in the host, and harvested 14 
days later. They were then implanted in the renal capsule of syngenic or 
allogenic mice recipients and analysed. The result was successful in vivo cell 
delivery with no significant antigenic response [78]. The greatest concern with 
the applicability of such a method is that the renal capsule itself is a privileged 
site that induces tolerance [79]. A further concern with such a method is the 
need to house the tissue in a bioreactor as, when tried in a human patient 
without use of a bioreactor, the graft did not have biomechanical strength until 
18 months [80].  
 
A human study of allogenic trachea tissue engineering used the patient’s 
forearm as a bioreactor [81]. The authors have subsequently employed this 
method in five patients with similar results in four of them: with withdrawal of 
immunosuppression, the patients tolerated the grafts well [18]. In one patient 
however, the graft was not immune tolerant at withdrawal of 
immunosuppression. The host immune response led to the appropriate 
resoprtion of the donor mucosa. However, the donor cartilage was afforded 
considerable immunoprotection only by the immunosuppression [82]. The 
requirement for immunosuppression would be largely unsuitable for the 
transplant and neonatal populations. For the moment, using the host is not a 
feasible option for an immunosuppression-free graft but provide a potential 
and viable alternative for the future.  
 
External bioreactors are currently the preferred option for growing autologous 
cells as they remove the potential for host morbidity and could, in theory, be 
made rapid and cost-effective. Bioreactors do have to, however, provide an 
environment that improves mass transfer, allows perfusion of vascular 
structures, and provides biocompartmentation as needed [83, 84]. The 
development of the rotating bed bioreactor leads to high rates of mass 
transfer and improved oxygenation of the tissue due to the shear stress [85, 
86]. Simultaneous transmural and axial flow within the material increases both 
the mechanical strength of the scaffold and the vascular development of the 
seeded cells [87, 88]. In theory, cell culture in the bioreactor and inclusion of 
factors could minimize the immune response and maximise viability of the 
graft due to the greater theoretical control afforded by an extrinsic method. 
Autologous cells could in theory also be grown to the scale required for whole 
organ engineering. 
3 Immunological outcomes for tissue engineered organs 
3.1 Lessons from case studies 
 
Functional organ replacement is the ultimate aim of tissue engineering. Tissue 
engineering to date has seen major successes in using scaffolds alone or 
scaffolds plus cells to reconstruct body tissues. Functional organ replacement 
is a future endeavour, but one that is no longer enshrined in mythology [89]. 
Successful attempts to create in vitro organ models include the production of 
the heart [90], liver [91, 92], lung [93], and recently the kidney [94]. 
 
Proof-of-principle trials have demonstrated both that there is minimal humoral 
immune reaction towards decellularized tissues and that recellularization is 
effective with no neoplastic element [21, 36, 95]. Thus, Macchiarini and 
colleagues performed the first tissue-engineered allogenic tracheal transplant 
in 2008. There were no signs of anti-donor antibodies or inflammation at 
follow up [15]. Gonfiotti et al have recently published a five-year follow up of a 
subsequent case of tissue engineered airway transplantation [36, 95]. The 
tissue-engineered trachea was open, well vascularised with respiratory 
epithelium, had normal ciliary function, and normal mucus clearance. 
However, the patient developed stenosis in the native trachea close to the 
proximal anastomotic site. Certainly, identifying ways to minimize scarring 
given the local immune response to the changing environment is an important 
avenue of research [14]. These results are not reproducible: in another trial in 
which a 76 year old patient with non-resectable tracheal stenosis was given a 
tissue-engineered transplant [20]. The patient passed away shortly thereafter 
from a cardiac arrest secondary to severe stenosis of the coronary arteries. 
However, at autopsy, the anastomoses were intact, the submucosa had 
reformed, there was one layer of squamous epithelium, neovascularization 
was occurring (lumina of capillaries and red platelets were visible), and the 
seeded chondrocytes were intact.  
 
Xenogenic human case studies have also been performed. Vaginal organs 
were engineered using allogenic cells and xenogenic scaffolds. In these 
patients, the scaffolds were derived from decellularized porcine small intestine 
submucosa. However, the patients’ own epithelial and muscle cells were 
cultured, expanded, and seeded onto these biomaterials. At yearly biopsy, the 
vaginal structure comprised three layers: epithelium, matrix, and muscle. 
Furthermore, the patients reported improved sexual function. No significant 
detrimental immune response was recorded [8]. Xenogenic materials, such as 
used in this study, may prove advantageous as they are more readily 
producible and when “cloaked” with autologous cells, appear to be afforded 
some immunoprotection. 
 
The concept of immunocloaking is also being explored in developing 
functional pancreatic islet cells for the treatment-resistant Diabetes [96, 97]. 
An initial investigation into islet cell transplantation provided reproducible 
success in the short-term [98]. However, long-term insulin independence has 
not been achieved [99]. Several solutions have been suggested including the 
inclusion of laminin and collagen IV, microencapsulation, and immunocloaking. 
Conrad et al bioengineered a scaffold based on decellularized pancreas 
extracellular matrix and mesenchymal stem cell / islet cell co-culture, 
generating functional endocrine tissue and reversing the diabetic state [89, 
100]. Therefore, protecting the graft from the host immune response is a key 
predictor of success in case trials. 
 
Creating blood vessels is vital not only for cardiovascular uses but also to 
develop a blood supply for more complicated grafts at other sites. The growth 
of blood vessels using bio-engineered scaffolds is progressing. Olaussen et al 
were able to transplant the first tissue engineered allogenic vessels into two 
pediatric patients. These grafts did not have any antibodies to Major 
Histocompatibility Complex I or II at follow up and remained patent with good 
response to pressure [24]. Acellular heart cadaveric extracellular matrix has 
been assessed in mice, but leads to clots even when transplanted with 
anticoagulation. By relining vascular conduits with rat aortic endothelial cells, 
a less thrombogenic left ventricle with better contractility was created. The trial 
arms that involved recellularizing the brachiocephalic artery and the inferior 
vena cava and the brachiocephalic artery led to improved rat aortic 
endothelial cell proliferation and von Willebrand Factor and nitric oxide 
synthase expression. The expression of these factors decreased 
thrombogenicity, thereby improving graft outcome [101]. Further rat models 
have also managed to reseed decellularized rat hearts with cardiac 
endothelial cells. By 8 days post-seeding, under physiological load, the hearts 
could generate pump function equivalent to 2% of adult function in a modified 
working heart preparation [90]. These studies suggest the potential for 
functional myocardial tissue replacement. However, the need for additional 
factors raises questions about how such factors could be incorporated as 
these factors are, in themselves, immunogenic. 
 
An observational first-in-human trial of five patients demonstrated the efficacy 
of engineered autologous tissue grafts for nasal reconstruction following 
tumour resection. The selected patients possessed a greater than 50% alar 
subunit defect after non-melanoma excision on the alar lobule. The procedure 
for cellularisation of the graft involved expanding, seeding, and culturing 
autologous chondrocytes in serum onto collagen type I and II over four weeks. 
These grafts were remodelled into fibromuscular fatty structures similar to the 
tissue at the site of implantation. There were no adverse events reported 
following implantation and patient satisfaction was high at 1 year. However, 
no cartilage was present at 6 months. In goats, however, engineered nasal 
cartilage grafts implanted in the knee remain cartilaginous. What factors, if 
any, are necessary to maintain and develop these grafts are still unknown [13]. 
It may not even be necessary to maintain the cartilaginous graft if the 
remodelling into the scar provides the necessary properties as in this case.   
3.2 Innate immune response to biological scaffolds  
Even as trials are providing insight as to what is occurring macroscopically, 
there is a growing body of evidence to suggest that the innate and adaptive 
immune response can both promote and undermine the viability of these 
grafts. The innate immune response to biological scaffolds can lead to early 
failure of the graft but, even in the absence of early graft failure, may also 
have knock-on effects for graft function and viability long term. The initial 
injury of placing the graft provokes an inflammatory response. The terminal 
biochemistry of the graft surface then modulates the serum proteins that 
adsorb to it. Biomaterial adherent macrophage apoptosis is also increased by 
hydrophilic substrates in vivo. Hydrophilic substrates also decrease monocyte 
and macrophage adhesion and fusion used in an in vivo rate cage implant 
system [102]. For example, integrins bind less if the molecule is hydrophilic 
and anionic [41]. Passive modulation of the biomaterial surface properties 
may limit macrophage adhesion, activation, and fusion to foreign body giant 
cells [41].  
 
Promotion of a long-term constructive macrophage phenotype is vital in 
achieving graft tolerance [103]. The classical macrophage type, M1, is IL-
12high, IL-23high, IL-10low and produce IL-1β, IL-6, and TNFα. Through the 
action of these CCR7+ CD80+ and CD86+ macrophages, Th1 inflammation 
and infection is induced. These macrophages cause inflammatory 
extracellular matrix destruction and injury. Matrix degradation can be 
extremely valuable in tissue sites as its functionality is gone once appropriate 
cellular architecture has been restored. However, in some contexts matrix 
maintenance is fundamental to the suitability of the graft, particularly in 
structures that carry a lot of load (such as bone) or that are prone to 
dangerous collapse (such as the airway). This is in contrast to the M2 
macrophage subtype, which is IL-12low, IL-23high, and IL-10high. These 
macrophages are CD163+, CD206+, and ArgI+ and lead to tissue repair 
through activation and in conjunction with the Th2 subtype [104]. Thus, some 
of the scar formation that was found in clinical trials may reflect a valuable 
form of matrix degradation. The question then becomes, how do we modulate 
this macrophage phenotype? 
 
Xenogenic tissue culture models have provided some insight into the 
macrophage innate immune response. In porcine acellular bladder matrix 
combined with human urinary tissue, there was a time-dependent infiltration 
by CD8+CD80- cells accompanied by maturation to a CD163 phenotype. 
PPARγ signalling predominated in the polarization of macrophages from M1 
(CD80+) towards M2 (CD163+) [105].  One of the problems with the use of a 
porcine model is that there is a dearth of markers for porcine cells. Another 
study in mammalian ECM found that degradation from ECM bioscaffolds 
promotes M2 macrophage polarization in vitro leading to the migration and 
myogensis of smooth muscle progenitors from solubilized small intestine 
submucosa. The secretome of this constructive graft was similar to that of IL-4 
polarized M2 macrophages [106].  
 
3.3 Adaptive immune response to biological scaffolds  
Proof of principle studies in humans have already demonstrated that the 
humoral immune response does not destroy tissue-engineered biological 
scaffolds. However, there may still be a cellular immune response. Indeed, 
the Th1 response is associated with classical acute graft rejection [73, 107, 
108].  Ideally, a scaffold should have delayed degradation time, decreased 
sensitized T cell proliferation, and improved survival of donor-derived cells 
[58]. Measuring the survival and functionality of the graft in vivo is difficult. In 
vitro studies have demonstrated that graft survival is associated with 
decreased IL-2, IFNγ and increased IL-10 levels, Furthermore, in tolerant 
grafts, the factors IL-4, TLR2, an TLR4 and their gene expression have 
decreased inversely proportional to recellularization of grafts while TGF-B1 is 
proportional [109]. Although being able to analyse the graft is important, the 
real question is how to modulate the T cell response away from Th1 effector 
function and towards a Th2 tolerant phenotype by harnessing the 
macrophage M2 phenotype [69]. 
 
Transplant studies offer valuable insight into the adaptive immune response to 
grafts. Transplant recipients must take immunosuppression drugs, which 
contribute to graft failure and are toxic to the host. Ever since [110] 
demonstrated that there was specific unresponsiveness in rats with prolonged 
cardiac allograft survival after treatment with cyclosporins, researchers have 
been trying to come up with a way to conduct transplants without 
immunosuppression. Central tolerance is achieved by depleting reactive T 
cells in the thymus. In utero transplantation and non-myeloablative bone 
marrow transplantation leading to mixed chimerism have both been attempted 
in order to induce central tolerance [111, 112]. The latter has been 
demonstrated in a proof of principle study [111]. As regards peripheral 
tolerance, strategies have included co-stimulatory blockade by manipulating 
regulatory T cells or through tolerogenic dendritic cells [113, 114].  
 
In vitro studies have shown that decellularized scaffolds can circumvent the 
cell-mediated immune response and modulate this host response towards a 
favourable phenotype [57, 58, 115, 116]. The ONE study is currently 
assessing the roles of Treg cells, regulatory macrophages, and tolerogenic 
dendritic cells in redirecting the host response towards an M2 macrophage 
and Th2 lymphocyte phenotype in human transplantation [117-119]. This 
study will have profound implications for how immune tolerance to biological 
scaffolds is established and promoted especially in future trials [120].  
 4 Immune response to biomaterials in pediatric patients 
 
Pediatric patients represent an important population. Structural abnormalities 
in children that cause debilitating or life-threatening outcomes require surgery. 
Pediatric patients have different requirements to adults: surgery should 
preferably be one time only and any resulting graft should in theory survive 
the length of the adult lifespan. 3% of newborns have congenital 
malformations including 2% with bronchopulmonary problems and tracheal 
problems (including agenesis, tracheomalacia, and bronchomalacia) [121]. 
Congenital anomalies further affect the heart with 10,000 children requiring 
surgery each year. Finally, genitourinary tract problems affect 4% of livebirths, 
with gynaecological problems in particular [122, 123]. There are differences in 
the immune profile of children that have implications on the design and 
implementation of tissue engineered organs. A recent five-year follow-up of a 
tissue-engineered trachea transplanted into a 10-year old child using a 
decellularized autologous graft with allogenic cells has confirmed that the 
scaffold demonstrated long-term viability. However, there were initial 
interventions, and a method to achieve this replacement with lower morbidity 
and cost is warranted [124]. 
 
5.1 Profile of pediatric innate and adaptive immunity 
 
In the newborn, innate immune cells mount a different cytokine response to 
pathogens as compared to adults. IL-12, IFN1, and IFNγ decrease whereas 
IL-1β, IL-6, IL-23, and IL-10 increase [125]. Innate immunity of the newborn is 
polarized towards a high ratio of IL-6/TNFα production [126]. Serum collected 
from the newborn has increased IL-6/TNFα ratios as compared to cord blood. 
The cause of the hyperactive innate immune response may be due to 
negative regulation of the adaptive arm via IL-10. Type I IFNs feedback on IL-
10 production as well as regulation IL-1β pro-inflammation by counter-
regulating the IL-1R antagonist. IL-6 production is then due to both neonatal 
cellular (monocyte) and humoral (serum) factors. This production is then 
associated with elevations of IL-6 inducible reactants CRP and LPS-binding 
protein. [127]. An observational study of pre-term infants who developed 
sepsis noted that these infants had decreased monocyte class II antigen, 
again suggesting that the adaptive immune system is delayed [128]. This has 
led to the hypothesis that there is a later set point for coupling adaptive and 
innate immunity [128-130]. Physiologically this is logical: fetal T cells are 
highly responsive in cell culture to in vitro antigen stimulation, however, there 
are limited numbers of T cells as the newborn immune system must tolerate 
the mother’s for birth. Minimizing or modulating the innate immune response, 
particularly to synthetic biomaterials, will be important in ensuring graft 
survival in pediatric patients.  
 
Many in vivo and in vitro studies to date have described the deficiencies or 
immune deviation among T cells, B cells, and APCs in neonates [131]. There 
is limited IL-2 production and deficient proliferation by human neonatal T cells. 
Adult-like Th1 can be achieved and has been demonstrated in response to 
antigen exposure [132, 133]. It is not known how skewed this response is to 
the Th2 phenotype. Mouse CD4+ T cells of fetal origin mount Th-2 skewed 
responses in an antigen dose-dependent manner [134]. The transfer of 
neonatal TCR transgenic CD4+ T cells into adoptive neonatal hosts leads to 
the development of both Th1 and Th2 cell primary effector function after 
immunization. After re-exposure to antigen in vivo, neonatal Th1 but not Th2 
cells undergo apoptosis. This process can be inhibited by IL-4R or IL-13R 
specific blocking antibodies [135]. One study in pigs found that younger 
animals have site-appropriate tissue remodelling of small intestine submucosa 
extracellular matrix as compared to scaffolds from older animals. Furthermore, 
this remodelling was consistent with a dominant M2 and Th2 response, 
suggesting that tolerance was easier to achieve [136]. How the immune 
profile of a pediatric or neonatal patient will present towards a tissue-
engineered biomaterial is unclear. However, the upregulation of the innate 
immune response and downregulation of the adaptive suggests that initial 
immunoprotection say through cloaking could be particularly valuable as 
subsequent degradation would be more likely to produce a tolerogenic graft. 
 
4.2 Cell replacement and immune desensitisation 
 
Cell replacement following immune desensitisation has been proposed as a 
therapy for CNS diseases, particularly in neonates. The immune response 
mounted against stem cells often hampers in vivo investigations. Current 
research has recognised the need for immune modulation in order to carry out 
these transplantations in animal models [137]. Two recent reports have 
demonstrated conflicting results with neonatal tolerance to xenografts in rats. 
The first found that human embryonic stem cell-derived mesenchymal stem 
cells survived as long as eight weeks and with a dampened CD4+ 
inflammatory response when the rats were immune desensitised prior to the 
transplantation [138]. The conflicting study employed the same method but 
used human glial-restricted precursor cells from the foetus [139]. A third study 
demonstrated that the method was reproducible using the same embryonic 
stem cell-derived mesenchymal stem cells as the first study in rat joint 
cartilage [140]. However, when reproduced in three strains of neonatal 
immune-intact mice, using two different brain transplant regimes and three 
independent stem cell types, implanted cells were rapidly rejected [141]. The 
efficacy of immune desensitisation has yet to be fully determined, however 
this is still a promising technique for avoiding some of the cell-related immune 
response. 
4.3 Lessons from organ transplantation in pediatrics 
 
Tolerant pediatric transplants have unique T and B cell profiles. CD4+CD25+ 
Treg cells have been implicated in the development of neonatal tolerance to 
transplantation antigens [131]. In a mouse model, CD4+CD25+ Treg cells 
block CD8+ Treg cells which themselves downregulate the Th2 cell-mediated 
pathology in a neonatal transplantation model [142]. For those human 
pediatric patients who develop a tolerant transplant profile, studies have 
demonstrated a unique adaptive immunophenotype. For example, in liver 
transplant, tolerant patients have increased numbers of naïve CD4+RA+ and 
CD4+CD197+RA+ T cells and fewer CD4+CD197+RA- T cells. Furthermore, 
there were more inducible CD4+CD25+ T cells. These tolerant patients also 
had fewer CD19+CD127+ B cells and increased numbers of CD27-CD38+, 
IgD+, and unswitched memory CD27+ IgD+ IgM+ B cells [143]. How this 
switch occurs is still unknown but may relate to environmental or other 
antigenic factors. Harnessing and identifying this switch is vital in modulating 
a pediatric immune response response. 
 
Immunodepletion has been a much-researched technique for decreasing the 
antigenicity of the transplant. For example, high-risk acute leukaemia patients 
sometimes require transplants that cannot be granted by a fully matched 
family donor. The advantages of T cell depletion are decreased graft versus 
host disease, decreased toxicity to the organ, lessened need for 
immunosuppression, and lower early transplant-related mortality. Trials have 
shown that, with a high dose of T cell-depleted haematopoietic progenitor 
cells, no suppression is required to control graft rejection or graft versus host 
disease [144]. The event free survival is similar but there are important 
implications of immunodepletion. There may be delayed immune 
reconstitution, viral reactivation and other infectious complications, decreased 
graft versus leukaemia effect, an increased incidence of graft failure, and 
increased risk of Epstein Barr Virus associated lympho-proliferative disorder.  
 
Immunodepletion also reveals how T cell tolerance may occur. T cell receptor 
Vδ2 γδ T cells are implicated in host defence whereas Vδ1 γδ T cells have a 
role in modulating the immune response [145, 146]. Studies have role for γδ T 
cell reconstitution in improving event-free survival. For example, infection 
increases in the presence of low numbers of Vδ2 γδ T cells. There is also a 
significant impact of the maximum number of CD3+, CD4+, and CD8+ T cells 
and donor source on the Vδ2 γδ T cell recovery [147]. When Vδ1/Vδ2 ratio 
was assessed in a liver transplant cohort, it was found that, when the ratio 
was the highest, patients were more likely to be graft tolerant. Furthermore, 
the Vδ1 gene had a complementarity-determining region 3 sequence (100% 
homologous) among all tolerant patients and dominant in 6 out of 9 patients. 
This clone was also found in some of the normal livers but none of the 
rejected organs [148]. Grafts could in theory be modified or selected for 
favourable T cell phenotype. One could imagine a bioreactor in which the host 
immune response was mimicked and the graft manipulated using genetic and 
environmental means to promote a tolerant response. 
 
Conclusions  
Organ tissue engineering is still in its earlier days, but the questions have now 
changed from whether or not it is possible, to how to fully harness its potential. 
One of the greatest stumbling blocks to the use of xenogenic, allogenic, 
synthetic or de novo biological tissues is the continued ability of the graft to 
provoke an immune response in the host. The immunogenicity of grafts has 
implications both for the scale of production that may be achieved and also for 
the outcomes of grafts once transplanted into the host. Additionally, the 
pediatric population has a robust innate immune system but a fledgling 
adaptive immune response, which could present significant problems with the 
initial scarring and graft remodelling. One solution to solving the immune 
problem is to effectively cloak grafts in immune-neutral substances such as 
the extracellular matrix or peptides. Additionally, studies are finding 
techniques to suppress or harness the immune system to promote graft 
tolerance. Through the ONE study as well as further investigation into 
macrophage and T cell class switching, harnessing the immune response 
could overcome the major immunological barriers to whole organ tissue 
engineering. The questions (and beginnings of answers) presented here will 
continue to provide challenging questions for clinicians and researchers 
looking to implement and advance tissue engineering.   
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